Skip to content

Injections and ablative procedures

TL;DR — Procedures must be matched to a pain phenotype: epidural steroid injection targets radicular pain, not axial disc degeneration; intradiscal procedures target an uncertain discogenic construct; and basivertebral nerve ablation targets a narrowly selected Modic 1/2 vertebrogenic phenotype. Basivertebral ablation has the strongest randomized evidence among these axial procedures, with durability reported to five years, but industry involvement and selection criteria constrain generalization (Fischgrund 2018, PMID 29423885; Fischgrund 2020, PMID 32451777). Intradiscal biacuplasty and platelet-rich plasma have positive small trials, while methylene-blue results failed robust replication (Desai 2016, PMID 26689579; Schepers 2022, PMID 39238810; Kallewaard 2019, PMID 30730862).

Target first

Procedure Intended target Required phenotype Not established for
Epidural steroid Inflamed/compressed root Radicular pain Axial DDD alone
Intradiscal steroid Disc/endplate inflammation Selected discogenic/Modic subgroup Generic chronic low-back pain
Intradiscal biacuplasty Annular nociceptive fibers Discogenic pain Vertebrogenic pain
IDET Annular thermal modification Discogenic pain Routine use
PRP/BMAC/cells Tissue modulation/regeneration Trial-defined discogenic DDD Standard care
Methylene blue Neural/chemical modulation Discogenic pain Supported reproducible therapy
Ozone Disc decompression/oxidation, often herniation Selected disc pathology Established axial DDD care
Basivertebral ablation Intraosseous basivertebral nerve Chronic axial pain + Modic 1/2 Radiculopathy or nonspecific pain

Evidence hierarchy

Procedural literature is vulnerable to placebo effects, regression to the mean, co-interventions and selective follow-up. A persuasive study needs a credible sham or active comparator, blinded outcome assessment, predefined phenotype, attrition accounting and durable safety.

Design What it can show Main residual problem
Case series Feasibility and common harms No counterfactual
Single-arm prospective Trajectory after treatment Expectancy/natural history
Active-control RCT Comparative effectiveness Blinding difficult
Sham-controlled RCT Specific efficacy beyond procedure context Sham ethics/fidelity
Long-term extension Durability and late harms Attrition and crossover
Independent replication Transportability Often absent

Epidural steroid injection

Epidural corticosteroid aims to reduce nerve-root inflammation. The indication is radicular lumbosacral pain, not an MRI report of degeneration.

Systematic reviews generally find small, short-term benefits for radicular pain with limited evidence of durable functional or surgical avoidance effects (Shamliyan 2014, PMID 24787344; Manchikanti 2022, PMID 36288577).

Approach Anatomical access Specific hazards
Interlaminar Dorsal epidural space Dural puncture, spread variability
Transforaminal Targeted foraminal/root Vascular injection, neurological injury
Caudal Sacral hiatus Larger volume, less target specificity

Risks include infection, bleeding, dural puncture, transient hyperglycemia, steroid systemic effects and rare catastrophic vascular/neurological events. Anticoagulation, anatomy, steroid formulation and image guidance require explicit protocols.

Intradiscal thermal procedures

Intradiscal electrothermal therapy (IDET) heats annular tissue via a catheter; proposed mechanisms include collagen modification and nociceptor disruption. Evidence reviews found inconsistent results and methodological limitations (Derby 2008, PMID 18164457).

Biacuplasty uses bipolar cooled radiofrequency across the posterior annulus. A placebo-controlled trial reported benefit in selected discogenic pain (Kapural 2013, PMID 23279658). A multicenter randomized comparison with conventional medical management and its 12-month follow-up also reported improved outcomes (Desai 2016, PMID 26689579; Desai 2017, PMID 27570246).

Selection depended on a discogenic diagnosis, so uncertainty in the diagnostic construct travels into the efficacy estimate.

Basivertebral nerve ablation

Basivertebral nerve ablation creates an intraosseous radiofrequency lesion in vertebral bodies adjacent to symptomatic endplates.

Typical trial features included:

  • chronic axial low-back pain;
  • failure of conservative care;
  • Modic type 1 or 2 at specified lumbar levels;
  • minimum pain/disability thresholds;
  • exclusion of major radicular pain, symptomatic stenosis and other causes.

Randomized evidence

The SMART trial was prospective, multicenter, randomized, double-blind and sham-controlled (Fischgrund 2018, PMID 29423885). The INTRACEPT trial compared ablation with standard care and stopped enrollment early at interim analysis after superiority criteria were met (Khalil 2019, PMID 31229663).

Study/report Comparator/follow-up Main evidence contribution
SMART primary Sham Specific efficacy signal (PMID 29423885)
SMART 5-year arm Long-term treated cohort Durability signal; attrition/context (PMID 32451777)
INTRACEPT primary Standard care Comparative effectiveness (PMID 31229663)
INTRACEPT 12 months Treated/crossover follow-up Maintained improvement (PMID 34031220)
INTRACEPT 24 months Treatment arm Durability (PMID 35141653)
Three-trial pooled 5 years Pooled prospective cohorts Larger long-term descriptive estimate (PMID 39758714)

Trial results support a treatment-responsive vertebrogenic phenotype, but treatment response cannot be used to declare every Modic lesion causal. Sponsor involvement, narrow selection, crossover and lack of abundant independent sham replication remain material.

Safety and selection

Reported complications are generally uncommon in trials, but possible harms include transient radicular symptoms, pedicle breach, bleeding, infection, fracture and failure to improve. Osteoporosis, altered anatomy, prior surgery and lesion access affect risk.

Real-world prospective cohorts broaden setting but cannot replace randomized comparison (Schnapp 2024, PMID 39655088).

Intradiscal corticosteroid

Intradiscal glucocorticoid trials have focused on active discopathy/Modic change. Systematic review and meta-analysis reported short-term pain effects in selected patients with Modic changes, but durability was limited and definitions varied (Riegger 2023, PMID 37774181).

Disc puncture and infection risk must be weighed against transient benefit. Intradiscal steroid is not equivalent to epidural steroid.

Platelet-rich plasma

PRP preparations differ in platelet concentration, leukocytes, activation, volume and co-interventions. Studies also differ in discography requirements and degeneration grade.

Evidence Result direction Limitation
Early prospective trial Improvement signal Small, no definitive control (PMID 26814283)
PRP vs corticosteroid RCT Comparative improvement signal Single-center and formulation-specific (PMID 35053999)
RCT without Modic change Did not establish universal efficacy Narrow phenotype (PMID 39238810)
Systematic review Low-certainty positive signal Heterogeneity and bias (PMID 32607308)
Prospective concentration study Explored dose/response Nonrandomized (PMID 32869064)

PRP should remain investigational or governance-controlled; “autologous” does not mean risk-free or effective.

Bone marrow concentrate and cell products

Bone marrow concentrate is heterogeneous and is not equivalent to culture-expanded mesenchymal stromal cells or disc progenitor cells. A systematic review found limited, low-quality evidence for intradiscal bone-marrow concentrate (Hirase 2020, PMID 32782864).

Biologic injections introduce risks of discitis, neurological injury, ectopic tissue and unregulated manufacturing. A reported case of diffuse hyperplastic gliosis and cauda equina after stem-cell injections illustrates rare but severe uncertainty (Aoun 2019, PMID 31491761).

Methylene blue

An early randomized report generated interest, but questions were raised about implausibly large effects and study quality (Schiltenwolf 2011, PMID 21292395). A later multicenter randomized placebo-controlled IMBI study did not reproduce meaningful efficacy (Kallewaard 2019, PMID 30730862).

This sequence is a caution against adoption from one unusually positive small trial. Meta-analysis that pools nonreplicated studies can obscure this history (Guo 2019, PMID 30039642).

Ozone and nucleoplasty

Intradiscal oxygen–ozone and percutaneous decompression are used in some regions, mainly for contained herniation or radicular symptoms. Studies mix discogenic axial pain and herniation, limiting interpretation (Rahimzadeh 2018, PMID 30104895; Yadav 2024, PMID 38616603).

They should not be grouped with regenerative injection or basivertebral ablation: target, mechanism and phenotype differ.

Antibiotics for Modic change

The hypothesis that low-grade bacterial infection causes some Modic change led to antibiotic trials. The Norwegian AIM trial did not support routine antibiotics; cost-utility analysis also did not support adoption (Grotle 2020, PMID 32546490).

Exploratory cytokine subgroup work does not overcome a negative main clinical strategy (Bråten 2023, PMID 37252109). Prolonged antibiotics add adverse effects and antimicrobial-resistance costs.

Comparative evidence gaps

Few trials directly compare:

  • high-quality rehabilitation versus basivertebral ablation;
  • basivertebral ablation versus fusion in a shared phenotype;
  • biacuplasty versus sham with independent replication;
  • standardized PRP versus placebo;
  • procedures stratified by quantitative endplate/disc biomarkers;
  • procedure plus rehabilitation versus either alone.

Cross-trial comparisons are unreliable because eligibility and diagnostic constructs differ.

Minimum procedural dataset

Domain Required report
Phenotype Axial/radicular; duration; neurological findings
Imaging Levels, Pfirrmann, Modic, herniation/stenosis
Diagnostic test Discography/block protocol if used
Product/device Manufacturer, lot, preparation, dose
Technique Imaging guidance, target, parameters
Comparator Sham fidelity or active care content
Co-interventions Medicines and rehabilitation
Outcomes Pain, ODI, participation, adverse events
Follow-up Attrition, crossover, reintervention
Funding/conflict Sponsor role and investigator ties

Evidence deepening: discriminating findings (2026-08-30)

The added evidence below was selected to change interpretation, not merely increase citation count. Each result is kept within its studied phenotype and design.

Evidence Quantified or mechanistic finding Consequence for interpretation
Intradiscal steroid injection for the treatment of chronic non-specific low back pain in patients with Modic type 1 change (Mu 2023, PMID 37140287) A clinical study evaluated intradiscal steroid injection specifically in chronic nonspecific pain with Modic type 1 change. Endplate-active phenotyping may modify response, but does not establish a durable disc-restorative effect.
A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic low back pain (Peng 2010, PMID 20167430) A randomized placebo-controlled trial reported benefit from intradiscal methylene blue for chronic discogenic pain. The striking early signal requires interpretation alongside later replication and procedural-blinding concerns.
Efficacy of Antibiotics for Chronic Low Back Pain With Disc Herniation: A Randomized Clinical Trial (Cicuttini 2026, PMID 42149593) A randomized trial tested antibiotics for chronic low-back pain with disc herniation. Antibiotic efficacy cannot be generalized across Modic, herniation and nonspecific phenotypes.
A systematic review and network meta-analysis comparing different epidural steroid injection approaches (Mahmoud 2024, PMID 37700550) A network meta-analysis compared epidural-steroid approaches. Route comparisons address radicular delivery and should not be imported into axial discogenic pain.
Epidural steroid compared to placebo injection in sciatica: a systematic review and meta-analysis (Verheijen 2021, PMID 33974132) A placebo-controlled meta-analysis examined epidural steroid for sciatica. Any short-term radicular effect is evidence for a different target than degeneration itself.
Effectiveness of intradiscal ozone injections for treating pain following herniated lumbar disc: A systematic review and meta-analysis (Chang 2024, PMID 38905033) An ozone meta-analysis reported higher six-month success than steroid (OR 3.95, 95% CI 2.44–6.39) in herniated-disc cohorts. Comparator quality, setting and herniation phenotype limit inference for axial DDD.

Controversy carried forward

These additions narrow several claims but do not create a diagnostic gold standard. Where an imaging, molecular or treatment-response signal conflicts with sham-controlled, longitudinal or population evidence, the conflict is retained as a selection and transportability problem rather than resolved by vote.

Open questions

  • Can basivertebral ablation benefits be replicated in independent sham-controlled trials and broader but still coherent phenotypes? (Fischgrund 2018, PMID 29423885)
  • Which Modic features predict specific benefit rather than general prognosis? (Khalil 2019, PMID 31229663)
  • Does biacuplasty outperform a credible sham under contemporary selection? (Kapural 2013, PMID 23279658)
  • What standardized PRP composition and dose should be tested? (Hirase 2020, PMID 32607308)
  • How should rare late biologic harms be captured across registries? (Aoun 2019, PMID 31491761)

References

  1. Fischgrund JS, Rhyne A, Franke J, et al. Intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: a prospective randomized double-blind sham-controlled multi-center study. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2018;27(5):1146-1156. PMID 29423885
  2. Fischgrund JS, Rhyne A, Macadaeg K, et al. Long-term outcomes following intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 5-year treatment arm results from a prospective randomized double-blind sham-controlled multi-center study. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2020;29(8):1925-1934. PMID 32451777
  3. Desai MJ, Kapural L, Petersohn JD, et al. A Prospective, Randomized, Multicenter, Open-label Clinical Trial Comparing Intradiscal Biacuplasty to Conventional Medical Management for Discogenic Lumbar Back Pain. Spine. 2016;41(13):1065-1074. PMID 26689579
  4. Schepers MO, Groot D, Kleinjan EM, et al. Effectiveness of intradiscal platelet rich plasma for discogenic low back pain without Modic changes: A randomized controlled trial. Interventional pain medicine. 2022;1(1):100011. PMID 39238810
  5. Kallewaard JW, Wintraecken VM, Geurts JW, et al. A multicenter randomized controlled trial on the efficacy of intradiscal methylene blue injection for chronic discogenic low back pain: the IMBI study. Pain. 2019;160(4):945-953. PMID 30730862
  6. Shamliyan TA, Staal JB, Goldmann D, et al. Epidural steroid injections for radicular lumbosacral pain: a systematic review. Physical medicine and rehabilitation clinics of North America. 2014;25(2):471-89.e1-50. PMID 24787344
  7. Manchikanti L, Knezevic E, Latchaw RE, et al. Comparative Systematic Review and Meta-Analysis of Cochrane Review of Epidural Injections for Lumbar Radiculopathy or Sciatica. Pain physician. 2022;25(7):E889-E916. PMID 36288577
  8. Derby R, Baker RM, Lee CH, et al. Evidence-informed management of chronic low back pain with intradiscal electrothermal therapy. The spine journal : official journal of the North American Spine Society. 2008;8(1):80-95. PMID 18164457
  9. Kapural L, Vrooman B, Sarwar S, et al. A randomized, placebo-controlled trial of transdiscal radiofrequency, biacuplasty for treatment of discogenic lower back pain. Pain medicine (Malden, Mass.). 2013;14(3):362-73. PMID 23279658
  10. Desai MJ, Kapural L, Petersohn JD, et al. Twelve-Month Follow-up of a Randomized Clinical Trial Comparing Intradiscal Biacuplasty to Conventional Medical Management for Discogenic Lumbar Back Pain. Pain medicine (Malden, Mass.). 2017;18(4):751-763. PMID 27570246
  11. Khalil JG, Smuck M, Koreckij T, et al. A prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain. The spine journal : official journal of the North American Spine Society. 2019;19(10):1620-1632. PMID 31229663
  12. Smuck M, Khalil J, Barrette K, et al. Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 12-month results. Regional anesthesia and pain medicine. 2021;46(8):683-693. PMID 34031220
  13. Koreckij T, Kreiner S, Khalil JG, et al. Prospective, randomized, multicenter study of intraosseous basivertebral nerve ablation for the treatment of chronic low back pain: 24-Month treatment arm results. North American Spine Society journal. 2021;8:100089. PMID 35141653
  14. Khalil JG, Truumees E, Macadaeg K, et al. Intraosseous basivertebral nerve ablation: A 5-year pooled analysis from three prospective clinical trials. Interventional pain medicine. 2024;3(4):100529. PMID 39758714
  15. Schnapp W, Schnapp M, Gottlieb J, et al. Prospective cohort study of basivertebral nerve ablation for chronic low back pain in a real-world setting: 12 months follow-up. Interventional pain medicine. 2024;3(4):100446. PMID 39655088
  16. Riegger M, Le H, van Kuijk SMJ, et al. Intradiscal Glucocorticoid Injection in Discogenic Back Pain and Influence on Modic Changes: A Systematic Review and Meta-analysis of RCTs. Pain physician. 2023;26(5):E449-E465. PMID 37774181
  17. Levi D, Horn S, Tyszko S, et al. Intradiscal Platelet-Rich Plasma Injection for Chronic Discogenic Low Back Pain: Preliminary Results from a Prospective Trial. Pain medicine (Malden, Mass.). 2016;17(6):1010-22. PMID 26814283
  18. Akeda K, Ohishi K, Takegami N, et al. Platelet-Rich Plasma Releasate versus Corticosteroid for the Treatment of Discogenic Low Back Pain: A Double-Blind Randomized Controlled Trial. Journal of clinical medicine. 2022;11(2). PMID 35053999
  19. Hirase T, Jack Ii RA, Sochacki KR, et al. Systemic Review: Is an Intradiscal Injection of Platelet-Rich Plasma for Lumbar Disc Degeneration Effective? Cureus. 2020;12(6):e8831. PMID 32607308
  20. Jain D, Goyal T, Verma N, et al. Intradiscal Platelet-Rich Plasma Injection for Discogenic Low Back Pain and Correlation with Platelet Concentration: A Prospective Clinical Trial. Pain medicine (Malden, Mass.). 2020;21(11):2719-2725. PMID 32869064
  21. Hirase T, Jack RA, Sochacki KR, et al. Systematic Review: Is Intradiscal Injection of Bone Marrow Concentrate for Lumbar Disc Degeneration Effective? Cureus. 2020;12(7):e9045. PMID 32782864
  22. Aoun SG, Peinado Reyes V, El Ahmadieh TY, et al. Stem cell injections for axial back pain: a systematic review of associated risks and complications with a case illustration of diffuse hyperplastic gliosis resulting in cauda equina syndrome. Journal of neurosurgery. Spine. 2019;31(6):906-913. PMID 31491761
  23. Schiltenwolf M, Fischer C, Kunz P. How perfect studies may be? Comment on Peng et al. A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic low back pain. Pain 2010;149:124-9. Pain. 2011;152(4):954. PMID 21292395
  24. Guo X, Ding W, Liu L, et al. Intradiscal Methylene Blue Injection for Discogenic Low Back Pain: A Meta-Analysis. Pain practice : the official journal of World Institute of Pain. 2019;19(1):118-129. PMID 30039642
  25. Rahimzadeh P, Imani F, Ghahremani M, et al. Comparison of percutaneous intradiscal ozone injection with laser disc decompression in discogenic low back pain. Journal of pain research. 2018;11:1405-1410. PMID 30104895
  26. Yadav RK, Sherpa T, Hamal PK, et al. Clinical Outcome for Lumbar Disc Herniation Treatment with Intradiscal Oxygen-ozone Therapy. Journal of Nepal Health Research Council. 2024;21(4):684-688. PMID 38616603
  27. Grotle M, Bråten LC, Brox JI, et al. Cost-utility analysis of antibiotic treatment in patients with chronic low back pain and Modic changes: results from a randomised, placebo-controlled trial in Norway (the AIM study). BMJ open. 2020;10(6):e035461. PMID 32546490
  28. Bråten LCH, Gjefsen E, Gervin K, et al. Cytokine Patterns as Predictors of Antibiotic Treatment Effect in Chronic Low Back Pain with Modic Changes: Subgroup Analyses of a Randomized Trial (AIM Study). Journal of pain research. 2023;16:1713-1724. PMID 37252109
  29. Mu XP, Wei XH, Chen SM, Ou YF, Wei MK, Wei JX, et al. Intradiscal steroid injection for the treatment of chronic non-specific low back pain in patients with Modic type 1 change. European review for medical and pharmacological sciences. 2023;27(8):3372-3382. PMID 37140287
  30. Peng B, Pang X, Wu Y, Zhao C, Song X. A randomized placebo-controlled trial of intradiscal methylene blue injection for the treatment of chronic discogenic low back pain. Pain. 2010;149(1):124-129. PMID 20167430
  31. Cicuttini FM, Wluka AE, Pan F, O'Sullivan R, Leder K, Cheng AC, et al. Efficacy of Antibiotics for Chronic Low Back Pain With Disc Herniation: A Randomized Clinical Trial. JAMA network open. 2026;9(5):e2612848. PMID 42149593
  32. Mahmoud AM, Shawky MA, Farghaly OS, Botros JM, Alsaeid MA, Ragab SG, et al. A systematic review and network meta-analysis comparing different epidural steroid injection approaches. Pain practice : the official journal of World Institute of Pain. 2024;24(2):341-363. PMID 37700550
  33. Verheijen EJA, Bonke CA, Amorij EMJ, Vleggeert-Lankamp CLA. Epidural steroid compared to placebo injection in sciatica: a systematic review and meta-analysis. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society. 2021;30(11):3255-3264. PMID 33974132
  34. Chang MC, Choo YJ, Denis I, Mares C, Majdalani C, Yang S, et al. Effectiveness of intradiscal ozone injections for treating pain following herniated lumbar disc: A systematic review and meta-analysis. Journal of back and musculoskeletal rehabilitation. 2024;37(5):1131-1139. PMID 38905033